Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Int J Mol Sci ; 22(9)2021 Apr 21.
Article in English | MEDLINE | ID: mdl-33919289

ABSTRACT

Spinal muscular atrophy (SMA) type 1 is a severe infantile autosomal-recessive neuromuscular disorder caused by a survival motor neuron 1 gene (SMN1) mutation and characterized by progressive muscle weakness. Without supportive care, SMA type 1 is rapidly fatal. The antisense oligonucleotide nusinersen has recently improved the natural course of this disease. Here, we investigated, with a functional proteomic approach, cerebrospinal fluid (CSF) protein profiles from SMA type 1 patients who underwent nusinersen administration to clarify the biochemical response to the treatment and to monitor disease progression based on therapy. Six months after starting treatment (12 mg/5 mL × four doses of loading regimen administered at days 0, 14, 28, and 63), we observed a generalized reversion trend of the CSF protein pattern from our patient cohort to that of control donors. Notably, a marked up-regulation of apolipoprotein A1 and apolipoprotein E and a consistent variation in transthyretin proteoform occurrence were detected. Since these multifunctional proteins are critically active in biomolecular processes aberrant in SMA, i.e., synaptogenesis and neurite growth, neuronal survival and plasticity, inflammation, and oxidative stress control, their nusinersen induced modulation may support SMN improved-expression effects. Hence, these lipoproteins and transthyretin could represent valuable biomarkers to assess patient responsiveness and disease progression.


Subject(s)
Genetic Therapy , Oligonucleotides/pharmacology , Proteome/analysis , Spinal Muscular Atrophies of Childhood/therapy , Child, Preschool , Female , Humans , Infant , Male , Oligonucleotides/therapeutic use , Oligonucleotides, Antisense/pharmacology , Oligonucleotides, Antisense/therapeutic use , Spinal Muscular Atrophies of Childhood/cerebrospinal fluid , Spinal Muscular Atrophies of Childhood/drug therapy , Spinal Muscular Atrophies of Childhood/genetics
3.
Neurol Sci ; 41(3): 497-508, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31792719

ABSTRACT

Many neurological diseases may cause acute respiratory failure (ARF) due to involvement of bulbar respiratory center, spinal cord, motoneurons, peripheral nerves, neuromuscular junction, or skeletal muscles. In this context, respiratory emergencies are often a challenge at home, in a neurology ward, or even in an intensive care unit, influencing morbidity and mortality. More commonly, patients develop primarily ventilatory impairment causing hypercapnia. Moreover, inadequate bulbar and expiratory muscle function may cause retained secretions, frequently complicated by pneumonia, atelectasis, and, ultimately, hypoxemic ARF. On the basis of the clinical onset, two main categories of ARF can be identified: (i) acute exacerbation of chronic respiratory failure, which is common in slowly progressive neurological diseases, such as movement disorders and most neuromuscular diseases, and (ii) sudden-onset respiratory failure which may develop in rapidly progressive neurological disorders including stroke, convulsive status epilepticus, traumatic brain injury, spinal cord injury, phrenic neuropathy, myasthenia gravis, and Guillain-Barré syndrome. A tailored assistance may include manual and mechanical cough assistance, noninvasive ventilation, endotracheal intubation, invasive mechanical ventilation, or tracheotomy. This review provides practical recommendations for prevention, recognition, management, and treatment of respiratory emergencies in neurological diseases, mostly in teenagers and adults, according to type and severity of baseline disease.


Subject(s)
Emergencies , Intubation, Intratracheal , Nervous System Diseases/complications , Respiration, Artificial , Respiratory Insufficiency/etiology , Respiratory Insufficiency/therapy , Tracheotomy , Humans
4.
Neurol Sci ; 39(11): 1961-1964, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30043247

ABSTRACT

Nusinersen is the first approved drug to treat spinal muscular atrophy (SMA). Its periodic intrathecal delivery may cause psychological burden in infants and in their parents. We report our experience during expanded access program (EAP) for type 1 SMA in a single Italian center. Because of the occurrence of stress emotional states, anxious reactions and fear before, during, and after lumbar puncture (LP), a specific psychological intervention was implemented based on regulation of emotions, anticipatory expectations, and post-event attributions. Activities included the use of fairy tales, distraction, music play through listening preferred cartoon themes in the youngest children, and contextual games and solution of fun riddle quizzes in the oldest ones. State anxiety greatly reduced in children and their parents. Treatment of psychological aspects should therefore become an integral part of health care in SMA infants and children during Nusinersen treatment.


Subject(s)
Oligonucleotides, Antisense/administration & dosage , Oligonucleotides/administration & dosage , Spinal Muscular Atrophies of Childhood/drug therapy , Spinal Muscular Atrophies of Childhood/psychology , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Injections, Spinal/methods , Italy , Male , Treatment Outcome
5.
Am J Crit Care ; 20(5): 405-9, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21885463

ABSTRACT

Neutrophil gelatinase-associated lipocalin is one of the most promising biomarkers for the diagnosis of acute kidney injury. An increase in the level of neutrophil gelatinase-associated lipocalin is a good predictor of acute kidney injury and is associated with an increase in the serum level of creatinine. Two victims of a mudslide in Messina, Italy, initially had crush syndrome followed by development of acute kidney injury. The development of acute kidney injury is the second most common cause of death after large earthquakes and other natural disasters, but at the same time, crush-related acute kidney injury is one of the few life-threatening complications of crush injuries that can be reversed if diagnosed early and treated. In this case, measuring the level of neutrophil gelatinase-associated lipocalin enabled early diagnosis of acute kidney injury and anticipation of the changes in levels of conventional markers such as creatinine.


Subject(s)
Crush Syndrome/physiopathology , Landslides , Lipocalins/blood , Proto-Oncogene Proteins/blood , Acute Kidney Injury/diagnosis , Acute Kidney Injury/physiopathology , Acute-Phase Proteins , Adult , Biomarkers/blood , Female , Hospitalization , Humans , Italy , Length of Stay , Lipocalin-2 , Middle Aged
6.
Int J Infect Dis ; 14(7): e572-9, 2010 Jul.
Article in English | MEDLINE | ID: mdl-19892577

ABSTRACT

INTRODUCTION: Post-neurosurgical nosocomial meningitis has become an important subgroup of bacterial meningitis in the hospital setting. The increase in meningitis caused by multidrug-resistant (MDR) Acinetobacter baumannii has resulted in a significant reduction in available treatment options. CASE REPORT AND LITERATURE REVIEW: We report the case of a 36-year-old man with a complex craniofacial trauma, who developed a nosocomial meningitis due to MDR A. baumannii that was cured by intrathecal colistin. The case is contextualized among all the published cases of Acinetobacter meningitis treated with topical colistin found through a MEDLINE search of the literature. To date, including the present case, eight reported cases of Acinetobacter meningitis have been treated with colistin administered by an intrathecal route and 24 by an intraventricular route. The daily dose of colistin used ranged from 1.6 mg every 24 h to 20 mg every 24 h in adult patients. The median time necessary to obtain cerebrospinal fluid sterilization was 4.1 days, and treatment was always successful even if in two cases Acinetobacter meningitis relapsed. Toxicity probably or possibly related to the topical administration of colistin was noted in five out of the 32 patients. CONCLUSIONS: Topical colistin can be an effective and safe treatment for MDR Acinetobacter meningitis.


Subject(s)
Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/administration & dosage , Colistin/administration & dosage , Craniocerebral Trauma/surgery , Drug Resistance, Multiple, Bacterial , Meningitis, Bacterial/drug therapy , Postoperative Complications/drug therapy , Acinetobacter Infections/drug therapy , Acinetobacter Infections/microbiology , Adult , Humans , Injections, Spinal , Male , Meningitis, Bacterial/microbiology , Postoperative Complications/microbiology , Treatment Outcome
7.
Interact Cardiovasc Thorac Surg ; 9(4): 588-92, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19581293

ABSTRACT

Cardiac surgery performed with cardiopulmonary bypass (CPB) may be complicated by hypotension due to low systemic vascular resistance (SVR). Often in those cases, hypotension is resistant to pressor catecholamines. We report six cases of norepinephrine-resistant postcardiotomy hypotension, treated by terlipressin (TP), a potent vasopressor agent. Between May 2007 and May 2008, we treated six patients with TP administration (1 mg bolus) for post CPB refractory vasodilatory hypotension. Analyzed parameters were: mean arterial pressure (m-AP), SVR, cardiac output index (CI), mean pulmonary pressure (m-PP), and lactate, at baseline (before TP bolus) and 3 h after injection. Before TP bolus, the average m-AP was 53.32+/-8.86 mmHg, the CI was 3.45+/-0.24 l/min/m(2), the SVR was 650+/-62.03 dyne*s/cm(5) and the arterial lactate level was 4.6+/-0.95 mmol/l. Three hours after the TP bolus, the m-AP increased to 81.83+/-9.71 mmHg (P=0.002), the CI decreased to 2.88+/-0.14 l/min/m(2) (P=0.002), the SVR increased to 1154+/-116 dyne*s/cm(5) (P=0.002), and arterial lactates decreased to 3.13+/-0.78 mmol/l (P=0.015), without significant modification of m-PP and CVP. We treated postoperative refractory low SVR hypotension by TP administration in bolus. Exogenous administration of TP normalized SVR and increased the systemic arterial pressure with a minimum effect on pulmonary pressure. Subsequently, the effect on systemic blood pressure enhanced urine output. No major collateral effects were observed. The administration of TP in bolus may result as a useful alternative for treating refractory low SVR hypotension post CPB.


Subject(s)
Cardiac Surgical Procedures/adverse effects , Cardiopulmonary Bypass/adverse effects , Hypotension/drug therapy , Lypressin/analogs & derivatives , Norepinephrine/administration & dosage , Vasoconstrictor Agents/administration & dosage , Vasoplegia/drug therapy , Aged , Aged, 80 and over , Blood Pressure/drug effects , Cardiac Output/drug effects , Central Venous Pressure/drug effects , Drug Resistance , Female , Humans , Hypotension/etiology , Hypotension/physiopathology , Injections , Lactic Acid/blood , Lypressin/administration & dosage , Male , Middle Aged , Retrospective Studies , Terlipressin , Time Factors , Treatment Outcome , Urination/drug effects , Vascular Resistance/drug effects , Vasoplegia/etiology , Vasoplegia/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...